Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 141

1.

Ultraviolet radiation inhibits mammary carcinogenesis in an ER negative murine model by a mechanism independent of vitamin D3.

Makarova AM, Frascari F, Davari P, Gorouhi F, Dutt PL, Wang L, Dhawan A, Wang GY, Green JE, Epstein EH.

Cancer Prev Res (Phila). 2018 Apr 10. pii: canprevres.0195.2017. doi: 10.1158/1940-6207.CAPR-17-0195. [Epub ahead of print]

PMID:
29636351
2.

Noncanonical hedgehog pathway activation through SRF-MKL1 promotes drug resistance in basal cell carcinomas.

Whitson RJ, Lee A, Urman NM, Mirza A, Yao CY, Brown AS, Li JR, Shankar G, Fry MA, Atwood SX, Lee EY, Hollmig ST, Aasi SZ, Sarin KY, Scott MP, Epstein EH Jr, Tang JY, Oro AE.

Nat Med. 2018 Mar;24(3):271-281. doi: 10.1038/nm.4476. Epub 2018 Feb 5.

PMID:
29400712
3.

Vitamin D3 Produced by Skin Exposure to UVR Inhibits Murine Basal Cell Carcinoma Carcinogenesis.

Makarova A, Wang G, Dolorito JA, Kc S, Libove E, Epstein EH Jr.

J Invest Dermatol. 2017 Dec;137(12):2613-2619. doi: 10.1016/j.jid.2017.05.037. Epub 2017 Jul 31.

PMID:
28774592
4.

Attenuation of UVR-induced vitamin D3 synthesis in a mouse model deleted for keratinocyte lathosterol 5-desaturase.

Makarova AM, Pasta S, Watson G, Shackleton C, Epstein EH Jr.

J Steroid Biochem Mol Biol. 2017 Jul;171:187-194. doi: 10.1016/j.jsbmb.2017.03.017. Epub 2017 Mar 19.

PMID:
28330720
5.

Differing tumor-suppressor functions of Arf and p53 in murine basal cell carcinoma initiation and progression.

Wang GY, Wood CN, Dolorito JA, Libove E, Epstein EH Jr.

Oncogene. 2017 Jun 29;36(26):3772-3780. doi: 10.1038/onc.2017.12. Epub 2017 Mar 6.

PMID:
28263978
6.

Risk Factors for Basal Cell Carcinoma Among Patients With Basal Cell Nevus Syndrome: Development of a Basal Cell Nevus Syndrome Patient Registry.

Solis DC, Kwon GP, Ransohoff KJ, Li S, Chahal HS, Ally MS, Peters MA, Schmitt-Burr K, Lindgren J, Bailey-Healy I, Teng JM, Epstein EH Jr, Tang JY.

JAMA Dermatol. 2016 Nov 30. doi: 10.1001/jamadermatol.2016.4347. [Epub ahead of print]

PMID:
27902821
7.

Inhibition of the hedgehog pathway in patients with basal-cell nevus syndrome: final results from the multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

Tang JY, Ally MS, Chanana AM, Mackay-Wiggan JM, Aszterbaum M, Lindgren JA, Ulerio G, Rezaee MR, Gildengorin G, Marji J, Clark C, Bickers DR, Epstein EH Jr.

Lancet Oncol. 2016 Dec;17(12):1720-1731. doi: 10.1016/S1470-2045(16)30566-6. Epub 2016 Nov 10.

PMID:
27838224
8.

Corrigendum to "Nanoelectroablation therapy for murine basal cell carcinoma" [Biochem. Biophys. Res. Commun. 424 (2012) 446-450].

Nuccitelli R, Tran K, Athos B, Kreis M, Nuccitelli P, Chang KS, Epstein EH Jr, Tang JY.

Biochem Biophys Res Commun. 2016 Nov 11;480(2):288. doi: 10.1016/j.bbrc.2016.10.078. No abstract available.

9.

Posaconazole, a Second-Generation Triazole Antifungal Drug, Inhibits the Hedgehog Signaling Pathway and Progression of Basal Cell Carcinoma.

Chen B, Trang V, Lee A, Williams NS, Wilson AN, Epstein EH Jr, Tang JY, Kim J.

Mol Cancer Ther. 2016 May;15(5):866-76. doi: 10.1158/1535-7163.MCT-15-0729-T. Epub 2016 Jan 28.

10.

Everything Is Connected.

Epstein EH.

J Invest Dermatol. 2015 Oct;135(10):2341-2344. doi: 10.1038/jid.2015.245. No abstract available.

11.

Effect of Calcium Channel Blockade on Vismodegib-Induced Muscle Cramps.

Ally MS, Tang JY, Lindgren J, Acosta-Raphael M, Rezaee M, Chanana AM, Epstein EH Jr.

JAMA Dermatol. 2015 Oct;151(10):1132-4. doi: 10.1001/jamadermatol.2015.1937. No abstract available.

PMID:
26200175
12.

The use of vismodegib to shrink keratocystic odontogenic tumors in patients with basal cell nevus syndrome.

Ally MS, Tang JY, Joseph T, Thompson B, Lindgren J, Raphael MA, Ulerio G, Chanana AM, Mackay-Wiggan JM, Bickers DR, Epstein EH Jr.

JAMA Dermatol. 2014 May;150(5):542-5. doi: 10.1001/jamadermatol.2013.7444.

13.

PI3K-AKT signaling is a downstream effector of retinoid prevention of murine basal cell carcinogenesis.

So PL, Wang GY, Wang K, Chuang M, Chiueh VC, Kenny PA, Epstein EH Jr.

Cancer Prev Res (Phila). 2014 Apr;7(4):407-17. doi: 10.1158/1940-6207.CAPR-13-0304. Epub 2014 Jan 21.

14.

Tazarotene: randomized, double-blind, vehicle-controlled, and open-label concurrent trials for basal cell carcinoma prevention and therapy in patients with basal cell nevus syndrome.

Tang JY, Chiou AS, Mackay-Wiggan JM, Aszterbaum M, Chanana AM, Lee W, Lindgren JA, Raphael MA, Thompson BJ, Bickers DR, Epstein EH Jr.

Cancer Prev Res (Phila). 2014 Mar;7(3):292-9. doi: 10.1158/1940-6207.CAPR-13-0305. Epub 2014 Jan 17.

15.

First-in-human trial of nanoelectroablation therapy for basal cell carcinoma: proof of method.

Nuccitelli R, Wood R, Kreis M, Athos B, Huynh J, Lui K, Nuccitelli P, Epstein EH Jr.

Exp Dermatol. 2014 Feb;23(2):135-7. doi: 10.1111/exd.12303. Epub 2014 Jan 23.

16.

Skin cancer: Basal cell carcinoma--pay your money, take your choice.

Epstein EH Jr.

Nat Rev Clin Oncol. 2013 Sep;10(9):489-90. doi: 10.1038/nrclinonc.2013.133. Epub 2013 Jul 23.

PMID:
23881034
17.

Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists.

Kim J, Aftab BT, Tang JY, Kim D, Lee AH, Rezaee M, Kim J, Chen B, King EM, Borodovsky A, Riggins GJ, Epstein EH Jr, Beachy PA, Rudin CM.

Cancer Cell. 2013 Jan 14;23(1):23-34. doi: 10.1016/j.ccr.2012.11.017. Epub 2013 Jan 3.

18.

Nanoelectroablation therapy for murine basal cell carcinoma.

Nuccitelli R, Sheikh S, Tran K, Athos B, Kreis M, Nuccitelli P, Chang KS, Epstein EH Jr, Tang JY.

Biochem Biophys Res Commun. 2012 Aug 3;424(3):446-50. doi: 10.1016/j.bbrc.2012.06.129. Epub 2012 Jul 4. Erratum in: Biochem Biophys Res Commun. 2016 Nov 11;480(2):288.

19.

Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome.

Tang JY, Mackay-Wiggan JM, Aszterbaum M, Yauch RL, Lindgren J, Chang K, Coppola C, Chanana AM, Marji J, Bickers DR, Epstein EH Jr.

N Engl J Med. 2012 Jun 7;366(23):2180-8. doi: 10.1056/NEJMoa1113538.

20.

Establishment of murine basal cell carcinoma allografts: a potential model for preclinical drug testing and for molecular analysis.

Wang GY, So PL, Wang L, Libove E, Wang J, Epstein EH Jr.

J Invest Dermatol. 2011 Nov;131(11):2298-305. doi: 10.1038/jid.2011.204. Epub 2011 Aug 11.

21.

Targeting superficial or nodular Basal cell carcinoma with topically formulated small molecule inhibitor of smoothened.

Tang T, Tang JY, Li D, Reich M, Callahan CA, Fu L, Yauch RL, Wang F, Kotkow K, Chang KS, Shpall E, Wu A, Rubin LL, Marsters JC Jr, Epstein EH Jr, Caro I, de Sauvage FJ.

Clin Cancer Res. 2011 May 15;17(10):3378-87. doi: 10.1158/1078-0432.CCR-10-3370. Epub 2011 May 10.

22.

Mommy - where do tumors come from?

Epstein EH Jr.

J Clin Invest. 2011 May;121(5):1681-3. doi: 10.1172/JCI57700. Epub 2011 Apr 25.

23.

Vitamin D3 inhibits hedgehog signaling and proliferation in murine Basal cell carcinomas.

Tang JY, Xiao TZ, Oda Y, Chang KS, Shpall E, Wu A, So PL, Hebert J, Bikle D, Epstein EH Jr.

Cancer Prev Res (Phila). 2011 May;4(5):744-51. doi: 10.1158/1940-6207.CAPR-10-0285. Epub 2011 Mar 24.

24.

Basal cell carcinomas arise from hair follicle stem cells in Ptch1(+/-) mice.

Wang GY, Wang J, Mancianti ML, Epstein EH Jr.

Cancer Cell. 2011 Jan 18;19(1):114-24. doi: 10.1016/j.ccr.2010.11.007. Epub 2011 Jan 6.

25.

High prevalence of vitamin D deficiency in patients with basal cell nevus syndrome.

Tang JY, Wu A, Linos E, Parimi N, Lee W, Aszterbaum M, Asgari MM, Bickers DR, Epstein EH Jr.

Arch Dermatol. 2010 Oct;146(10):1105-10. doi: 10.1001/archdermatol.2010.247.

26.

Novel investigational drugs for basal cell carcinoma.

So PL, Tang JY, Epstein EH.

Expert Opin Investig Drugs. 2010 Sep;19(9):1099-112. doi: 10.1517/13543784.2010.504714. Review.

27.

Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth.

Kim J, Tang JY, Gong R, Kim J, Lee JJ, Clemons KV, Chong CR, Chang KS, Fereshteh M, Gardner D, Reya T, Liu JO, Epstein EH, Stevens DA, Beachy PA.

Cancer Cell. 2010 Apr 13;17(4):388-99. doi: 10.1016/j.ccr.2010.02.027.

28.

Basal cell carcinoma chemoprevention with nonsteroidal anti-inflammatory drugs in genetically predisposed PTCH1+/- humans and mice.

Tang JY, Aszterbaum M, Athar M, Barsanti F, Cappola C, Estevez N, Hebert J, Hwang J, Khaimskiy Y, Kim A, Lu Y, So PL, Tang X, Kohn MA, McCulloch CE, Kopelovich L, Bickers DR, Epstein EH Jr.

Cancer Prev Res (Phila). 2010 Jan;3(1):25-34. doi: 10.1158/1940-6207.CAPR-09-0200.

29.

Loss of Blm enhances basal cell carcinoma and rhabdomyosarcoma tumorigenesis in Ptch1+/- mice.

Davari P, Hebert JL, Albertson DG, Huey B, Roy R, Mancianti ML, Horvai AE, McDaniel LD, Schultz RA, Epstein EH Jr.

Carcinogenesis. 2010 Jun;31(6):968-73. doi: 10.1093/carcin/bgp309. Epub 2009 Dec 8.

30.

Inverse association between serum 25(OH) vitamin D levels and non-melanoma skin cancer in elderly men.

Tang JY, Parimi N, Wu A, Boscardin WJ, Shikany JM, Chren MM, Cummings SR, Epstein EH Jr, Bauer DC; Osteoporotic Fractures in Men (MrOS) Study Group.

Cancer Causes Control. 2010 Mar;21(3):387-91. doi: 10.1007/s10552-009-9470-4.

31.

Primary cilia can both mediate and suppress Hedgehog pathway-dependent tumorigenesis.

Wong SY, Seol AD, So PL, Ermilov AN, Bichakjian CK, Epstein EH Jr, Dlugosz AA, Reiter JF.

Nat Med. 2009 Sep;15(9):1055-61. doi: 10.1038/nm.2011. Epub 2009 Aug 23.

32.

Elevated cutaneous Smad activation associates with enhanced skin tumor susceptibility in organ transplant recipients.

Harradine KA, Ridd K, Saunier EF, Clermont FF, Perez-Losada J, Moore DH, Epstein EH Jr, Bastian BC, Akhurst RJ.

Clin Cancer Res. 2009 Aug 15;15(16):5101-7. doi: 10.1158/1078-0432.CCR-08-3286. Epub 2009 Aug 11.

33.

Statin use and risk of basal cell carcinoma.

Asgari MM, Tang J, Epstein EH Jr, Chren MM, Warton EM, Quesenberry CP Jr, Go AS, Friedman GD.

J Am Acad Dermatol. 2009 Jul;61(1):66-72. doi: 10.1016/j.jaad.2009.02.011. Epub 2009 May 21.

34.

Basal cell carcinomas: attack of the hedgehog.

Epstein EH.

Nat Rev Cancer. 2008 Oct;8(10):743-54. doi: 10.1038/nrc2503. Review.

35.

Pharmacologic retinoid signaling and physiologic retinoic acid receptor signaling inhibit basal cell carcinoma tumorigenesis.

So PL, Fujimoto MA, Epstein EH Jr.

Mol Cancer Ther. 2008 May;7(5):1275-84. doi: 10.1158/1535-7163.MCT-07-2043.

36.

Topical thymidine dinucleotide treatment reduces development of ultraviolet-induced basal cell carcinoma in Ptch-1+/- mice.

Arad S, Zattra E, Hebert J, Epstein EH Jr, Goukassian DA, Gilchrest BA.

Am J Pathol. 2008 May;172(5):1248-55. doi: 10.2353/ajpath.2008.071117. Epub 2008 Apr 10.

37.

Case records of the Massachusetts General Hospital. Case 3-2008. An 80-year-old woman with cutaneous basal-cell carcinomas and cysts of the jaws.

Epstein EH, Shepard JA, Flotte TJ.

N Engl J Med. 2008 Jan 24;358(4):393-401. doi: 10.1056/NEJMcpc0707893. No abstract available.

PMID:
18216361
38.

Novel Hedgehog pathway targets against basal cell carcinoma.

Tang JY, So PL, Epstein EH Jr.

Toxicol Appl Pharmacol. 2007 Nov 1;224(3):257-64. Epub 2006 Dec 21. Review.

39.

Long-term establishment, characterization and manipulation of cell lines from mouse basal cell carcinoma tumors.

So PL, Langston AW, Daniallinia N, Hebert JL, Fujimoto MA, Khaimskiy Y, Aszterbaum M, Epstein EH Jr.

Exp Dermatol. 2006 Sep;15(9):742-50.

PMID:
16881970
40.

Obstacles to translation conference.

Epstein EH Jr, Gilchrest BA, Milstone LM.

J Invest Dermatol. 2006 Jul;126(7):1434-7. No abstract available.

41.

Identification of genetic loci for basal cell nevus syndrome and inflammatory bowel disease in a single large pedigree.

Panhuysen CI, Karban A, Knodle Manning A, Bayless TM, Duerr RH, Bailey-Wilson JE, Epstein EH Jr, Brant SR.

Hum Genet. 2006 Aug;120(1):31-41. Epub 2006 May 30.

PMID:
16733713
42.

Cancer. An anchor for tumor cell invasion.

Yuspa SH, Epstein EH Jr.

Science. 2005 Mar 18;307(5716):1727-8. No abstract available.

PMID:
15774745
43.

Anti-rejection drug treatment increases basal cell carcinoma burden in Ptch1+/- mice.

Vogt A, Hebert J, Hwang J, Lu Y, Epstein EH.

J Invest Dermatol. 2005 Jan;124(1):263-7.

44.

Inhibition of smoothened signaling prevents ultraviolet B-induced basal cell carcinomas through regulation of Fas expression and apoptosis.

Athar M, Li C, Tang X, Chi S, Zhang X, Kim AL, Tyring SK, Kopelovich L, Hebert J, Epstein EH Jr, Bickers DR, Xie J.

Cancer Res. 2004 Oct 15;64(20):7545-52.

45.

Adult stem cells: capturing youth from a bulge?

So PL, Epstein EH Jr.

Trends Biotechnol. 2004 Oct;22(10):493-6. Review.

PMID:
15450739
46.

Topical tazarotene chemoprevention reduces Basal cell carcinoma number and size in Ptch1+/- mice exposed to ultraviolet or ionizing radiation.

So PL, Lee K, Hebert J, Walker P, Lu Y, Hwang J, Kopelovich L, Athar M, Bickers D, Aszterbaum M, Epstein EH Jr.

Cancer Res. 2004 Jul 1;64(13):4385-9.

47.

Ornithine decarboxylase is a target for chemoprevention of basal and squamous cell carcinomas in Ptch1+/- mice.

Tang X, Kim AL, Feith DJ, Pegg AE, Russo J, Zhang H, Aszterbaum M, Kopelovich L, Epstein EH Jr, Bickers DR, Athar M.

J Clin Invest. 2004 Mar;113(6):867-75.

48.

Immunoprevention of basal cell carcinomas with recombinant hedgehog-interacting protein.

Vogt A, Chuang PT, Hebert J, Hwang J, Lu Y, Kopelovich L, Athar M, Bickers DR, Epstein EH Jr.

J Exp Med. 2004 Mar 15;199(6):753-61.

49.

Mutations in ATP2A2 in patients with Darier's disease.

Ikeda S, Mayuzumi N, Shigihara T, Epstein EH Jr, Goldsmith LA, Ogawa H.

J Invest Dermatol. 2003 Sep;121(3):475-7. No abstract available.

50.

Loss of kindlin-1, a human homolog of the Caenorhabditis elegans actin-extracellular-matrix linker protein UNC-112, causes Kindler syndrome.

Siegel DH, Ashton GH, Penagos HG, Lee JV, Feiler HS, Wilhelmsen KC, South AP, Smith FJ, Prescott AR, Wessagowit V, Oyama N, Akiyama M, Al Aboud D, Al Aboud K, Al Githami A, Al Hawsawi K, Al Ismaily A, Al-Suwaid R, Atherton DJ, Caputo R, Fine JD, Frieden IJ, Fuchs E, Haber RM, Harada T, Kitajima Y, Mallory SB, Ogawa H, Sahin S, Shimizu H, Suga Y, Tadini G, Tsuchiya K, Wiebe CB, Wojnarowska F, Zaghloul AB, Hamada T, Mallipeddi R, Eady RA, McLean WH, McGrath JA, Epstein EH.

Am J Hum Genet. 2003 Jul;73(1):174-87. Epub 2003 Jun 3.

Supplemental Content

Loading ...
Support Center